Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01529632 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

193

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: QVA149
DRUG: NVA237
DRUG: QAB149
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals